JP2023513124A5 - - Google Patents

Info

Publication number
JP2023513124A5
JP2023513124A5 JP2022547208A JP2022547208A JP2023513124A5 JP 2023513124 A5 JP2023513124 A5 JP 2023513124A5 JP 2022547208 A JP2022547208 A JP 2022547208A JP 2022547208 A JP2022547208 A JP 2022547208A JP 2023513124 A5 JP2023513124 A5 JP 2023513124A5
Authority
JP
Japan
Prior art keywords
cdr
amino acid
acid sequence
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022547208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513124A (ja
JP7772702B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017290 external-priority patent/WO2021163076A1/en
Publication of JP2023513124A publication Critical patent/JP2023513124A/ja
Publication of JP2023513124A5 publication Critical patent/JP2023513124A5/ja
Priority to JP2025187155A priority Critical patent/JP2026027362A/ja
Application granted granted Critical
Publication of JP7772702B2 publication Critical patent/JP7772702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022547208A 2020-02-10 2021-02-09 抗tmprss2抗体および抗原結合断片 Active JP7772702B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025187155A JP2026027362A (ja) 2020-02-10 2025-11-06 抗tmprss2抗体および抗原結合断片

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062972338P 2020-02-10 2020-02-10
US62/972,338 2020-02-10
US202063021016P 2020-05-06 2020-05-06
US63/021,016 2020-05-06
US202063094199P 2020-10-20 2020-10-20
US63/094,199 2020-10-20
PCT/US2021/017290 WO2021163076A1 (en) 2020-02-10 2021-02-09 ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025187155A Division JP2026027362A (ja) 2020-02-10 2025-11-06 抗tmprss2抗体および抗原結合断片

Publications (3)

Publication Number Publication Date
JP2023513124A JP2023513124A (ja) 2023-03-30
JP2023513124A5 true JP2023513124A5 (https=) 2024-02-14
JP7772702B2 JP7772702B2 (ja) 2025-11-18

Family

ID=74798119

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547208A Active JP7772702B2 (ja) 2020-02-10 2021-02-09 抗tmprss2抗体および抗原結合断片
JP2025187155A Pending JP2026027362A (ja) 2020-02-10 2025-11-06 抗tmprss2抗体および抗原結合断片

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025187155A Pending JP2026027362A (ja) 2020-02-10 2025-11-06 抗tmprss2抗体および抗原結合断片

Country Status (10)

Country Link
US (2) US11999799B2 (https=)
EP (1) EP4103619A1 (https=)
JP (2) JP7772702B2 (https=)
KR (1) KR20220140503A (https=)
CN (1) CN115427457A (https=)
AU (1) AU2021219671A1 (https=)
CA (1) CA3163164A1 (https=)
IL (1) IL294529A (https=)
MX (1) MX2022009476A (https=)
WO (1) WO2021163076A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806507B2 (en) 2020-12-22 2023-11-07 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
CA3202742A1 (en) * 2020-12-22 2022-06-30 Regina E. HERZLINGER Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion
US12133966B2 (en) 2020-12-22 2024-11-05 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
US20250019425A1 (en) * 2021-11-12 2025-01-16 Adrx, Inc. Transthyretin (ttr) monomer binding antibodies
US20250277059A1 (en) * 2022-04-12 2025-09-04 Riken Antibody used to treat coronavirus infection
CN116003611B (zh) * 2022-08-17 2024-02-27 中南大学湘雅医院 抗tmprss2抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DK1299727T3 (da) 2000-07-12 2009-06-15 Agensys Inc Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
US8354508B2 (en) 2006-07-21 2013-01-15 Diadexus, Inc. PRO115 antibody compositions and methods of use
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2285833B1 (en) 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
BR112014025339A8 (pt) 2012-04-16 2018-01-16 Regeneron Pharma método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo.
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
DK3422845T3 (da) 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
CN111936517B (zh) 2018-01-26 2025-04-18 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段

Similar Documents

Publication Publication Date Title
JP2023513124A5 (https=)
IL312961A (en) Anti-tmprss2 antibodies and antigen-binding fragments
JP2021511058A5 (https=)
RU2755724C2 (ru) Pd1/ctla4-связывающие вещества
TWI604852B (zh) 藉由拮抗il-6受體抑制腫瘤生長之方法
JP2021516973A5 (https=)
TWI831789B (zh) 二聚體及其用途
CN103536917B (zh) 干扰素在治疗肿瘤中的用途及相关的产品和方法
JP7754506B2 (ja) ポリオウイルス受容体(pvr)に対する抗体およびその使用
JP2024174962A (ja) Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
CN102884081A (zh) 用dll4拮抗剂治疗自身免疫疾病的方法
KR102399028B1 (ko) 이중-특이적 항원-결합 폴리펩티드
JP2021063092A (ja) B型肝炎表面抗原に対する抗体及びその使用
KR20230013125A (ko) 4-1bb 결합 단백질 및 이의 용도
AU2019226551A1 (en) Methods for altering body composition
CN116262135A (zh) 抗cd27抗体组合物及其用途
US20240082394A1 (en) Combination therapy for the treatment of cancer
CN116262790A (zh) 嵌合的抗cd27抗体组合物及其应用
TWI895253B (zh) 抗平足蛋白抗體
JP2026506070A (ja) 抗cntn4抗体及びその使用
WO2023178253A2 (en) Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
CA3212850A1 (en) Anti-egfrviii antibody drug conjugates and uses thereof
CN106963950B (zh) 用于治疗肿瘤的联合用药物
JP6737482B1 (ja) 抗ポドプラニン抗体
WO2024069240A2 (en) Cd38-binding fusion protein combination therapy